Bain Capital Private Credit reported total investment income of $173.3 million for the nine months ended September 30, 2026, a significant increase from $88.3 million in the prior year period. Net investment income grew to $83.1 million as the company expanded its investment portfolio to $2.4 billion at fair value, up from $1.68 billion at the end of 2025.
AIM ImmunoTech reported a net loss of $9.95 million for the nine months ended September 30, 2026, compared to $9.78 million in the prior year. The company significantly strengthened its balance sheet through equity offerings and warrant exercises, increasing total assets to $9.75 million and achieving a positive stockholders' equity of $7.08 million.
SES AI Corp reported total current assets of $161.6 million as of September 30, 2026, a decrease from $216.3 million at year-end 2025, primarily driven by a reduction in short-term investments. The company continues to incur losses and highlights risks related to its drone cell manufacturing, AI-based services, and the integration of UZ Energy.
Journey Medical Corp reported a 16.7% increase in total revenue to $53.4 million for the nine months ended September 30, 2026, compared to the prior year. The company significantly reduced its net loss from $10.2 million to $3.9 million over the same period, driven by improved operating margins and lower research and development expenses.
Pono Capital Four, Inc. reported a net income of $1,571,816 for the period from inception (January 2, 2026) through September 30, 2026, primarily driven by $2,346,853 in income earned on marketable securities held in the Trust Account. As a shell company, it maintains $122,346,853 in its Trust Account while reporting a shareholders' deficit of $2,654,584 due to the redemption value of Class A ordinary shares.
Gemini Space Station reported Q3 2026 total revenue of $40.9 million, a 19% year-over-year decline driven by a 73% drop in platform spot trading volume. Despite the revenue decline, the company improved its net loss by 63% year-over-year to $58.6 million through a 30% reduction in operating expenses and lower headcount.
Term
Q3 2026
“Operating expenses declined for a third consecutive quarter, and as we invest in growth, we intend to stay disciplined about where those dollars go. We’re clear-eyed about the work ahead and committed to getting it right: deepening our relationships with the customers who use Gemini, continuing to iterate, and investing where customers and markets are headed. We expect to be judged on results, and we intend to earn the confidence of our customers and shareholders one quarter at a time.”
Tyler Winklevoss, CEO of Gemini
“We started Gemini in 2014 because we believed crypto would change how people save, spend and move value, and we’re in this for the long term. Gemini 2.0 is our bet that the platforms that last will be the ones that own the regulated infrastructure underneath. We’re building ours to serve customers directly and to be something other platforms can build on.”
enCore Energy Corp. is a non-accelerated filer and smaller reporting company focused on uranium exploration and extraction. As of November 9, 2026, the company had 195,668,102 common shares outstanding and reported a history of negative operating cash flows while pursuing an expansion-by-acquisition strategy.
Cibus, Inc. reported a net loss of $21.9 million for the third quarter of 2026, with revenue increasing to $0.8 million from $0.6 million in the prior year period. The company's cash position improved slightly to $10.7 million as of September 30, 2026, supported by $31.0 million in net cash provided by financing activities during the first nine months of the year.
Spero Therapeutics reported that the FDA approved GSK’s NDA resubmission for Utebzi in June 2026, shifting the company's focus to the development of SP001. As of November 6, 2026, the company had 58,264,577 shares of common stock outstanding and continues to rely on milestone payments and royalties from its GSK partnership to fund operations.
CapsoVision reported Q3 2026 revenue of $3.6 million and a gross margin of 49%, while highlighting the recent FDA clearance and launch of its AI Highlights tool. The company also completed enrollment for its second-generation CapsoCam Colon study and raised approximately $19.5 million in net proceeds through a registered direct offering and ATM program during the quarter.
Term
Q3 2026
“The FDA clearance and subsequent U.S. launch of AI Highlights marks an important step forward for CapsoVision. Our four-camera, 360-degree panoramic capsule already provides physicians with a differentiated view of the small bowel. By combining that imaging capability with AI-assisted review, we believe we can reduce reading time, improve detection accuracy compared with manual review, and give physicians an additional level of diagnostic confidence.”
Johnny Wang, President and Chief Executive Officer
“At the same time, completing enrollment in our colon clinical study brings us closer to our planned FDA submission by year end, which we believe represents a substantially larger market opportunity. With the support of our existing shareholders through our recent financing, we are focused on translating these milestones into broader adoption and long-term growth.”
Johnny Wang, President and Chief Executive Officer
WhiteHawk Minerals Corp. reported Q3 2026 financial results including record production of 71.3 MMcfe/d and net income of $6.9 million. Concurrently, the company announced the $41.0 million acquisition of mineral and royalty interests in the Marcellus/Appalachian Basin from Three Rivers Royalty II, LLC. The company also declared a quarterly dividend of $0.50 per share.
Counterparty
Three Rivers Royalty II, LLC
“Continuing the momentum, WhiteHawk is benefiting from its base business and two-pronged acquisition strategy, driving an increase in Cash Available for Distribution and net asset value. We continue to benefit directly from our best-in-class operators’ performance and growth potential. We are particularly excited by EQT’s pending acquisition of Range, which brings together two of our largest Appalachia operators. We believe the combined company’s scale, inventory depth and low-cost structure are well aligned with WhiteHawk’s interests and further support the long-term development of our core mineral position. At the same time, our two-pronged acquisition strategy continues to deliver. Since our IPO, we have signed 22 acquisitions totaling $157.3 million, including 20 ground game transactions totaling over $11 million. We believe these transactions, and execution on our acquisition pipeline, will continue to drive meaningful value for shareholders in the short, medium and long term.”
Daniel Herz, Chairman, President and Chief Executive Officer
Altimmune, Inc. reported a net loss of $77.0 million for the nine months ended September 30, 2026, compared to $60.7 million in the prior year, driven by increased research and development expenses. The company significantly strengthened its balance sheet through public and direct offerings, ending the period with $495.6 million in total assets, including $265.1 million in cash and investments.
Standard Lithium Ltd. changed its functional currency from CAD to USD effective July 1, 2026, reflecting its advancing U.S. development projects. The company reported a carrying amount of $210.5 million for its equity method investment in the Smackover Lithium joint venture with Equinor as of September 30, 2026.
Net Power Inc. is a non-accelerated filer and emerging growth company focused on power generation technology. The filing highlights significant risks including a pause in Texas data center permits, the need for additional capital, and the full impairment of its La Porte Demonstration Facility assets.
First Keystone Corp reported a net income of $9.475 million for the nine months ended September 30, 2026, up from $6.775 million in the prior year period. Total assets grew significantly to $1.726 billion from $1.531 billion at year-end 2025, primarily driven by a $178 million increase in total deposits.
QuoteMedia Inc. reported a net loss of $1,140,614 for the nine months ended September 30, 2026, an improvement from the $1,720,585 loss in the prior year period. Revenue grew 11% to $16.6 million, while the company maintained a stockholders' deficit of $1,956,956 as of the end of the quarter.
Fluent, Inc. reported a net loss of $3.1 million for the third quarter of 2026, an improvement from a $7.6 million loss in the prior year period, driven by a 14% increase in revenue to $53.6 million. For the nine months ended September 30, 2026, the company generated $2.8 million in cash from operating activities compared to a $4.3 million outflow in 2025. Total shareholders' equity declined significantly from $18.2 million at the end of 2025 to $5.6 million as of September 30, 2026.
Upexi, Inc. reported fiscal first quarter 2027 results, highlighted by net income of $89.1 million, which was primarily driven by $102 million in unrealized gains on its digital asset treasury. The company significantly strengthened its balance sheet, reporting stockholders' equity of $49.2 million compared to a deficit in the prior quarter, and reduced its interest rate on BitGo borrowings from 11.5% to 7.5%.
Term
Q1 2027
“During the first quarter of fiscal 2027, we strengthened our balance sheet by increasing our Solana treasury to approximately 2.35 million SOL, increasing our cash on hand to $6.4 million, and increasing our stockholders’ equity to $49.2 million. Additionally, in September we successfully reduced the interest rate on our BitGo borrowings from 11.5% to 7.5%, a reduction we expect to lower annual interest expense by approximately $2.3 million.”
AVAX ONE TECHNOLOGY LTD. reported a net loss of $31.6 million for the nine months ended September 30, 2026, despite a significant increase in revenue to $7.8 million compared to $1.3 million in the prior year. The company's financial position was impacted by $10.9 million in unrealized losses on digital assets and $5.3 million in interest accretion on debentures, though it achieved a net income of $49.9 million in the third quarter due to a favorable market valuation swing of $55.1 million.
First Capital, Inc. reported net income of $14.2 million for the nine months ended September 30, 2026, up from $11.5 million in the prior year period, driven by higher net interest income. Total assets remained stable at $1.27 billion, while stockholders' equity decreased slightly to $135.7 million due to a significant increase in accumulated other comprehensive loss from unrealized losses on securities.
Wilco 63 Corp reported net income of $1.95 million for the quarter ended September 30, 2026, primarily driven by $2.10 million in interest earned on marketable securities held in its Trust Account. As a blank check company, it has not yet commenced operations or generated revenue, and it currently holds $232.28 million in its Trust Account following its June 2026 initial public offering.
GEN Restaurant Group reported a net loss of $17.3 million for the nine months ended September 30, 2026, compared to a $7.3 million loss in the prior year period, as restaurant operating expenses rose despite a slight decline in revenue. The company's total assets decreased to $247.2 million from $259.9 million at year-end 2025, while its cash position remained relatively stable at $2.9 million.
Virgin Galactic reported Q3 2026 financial results, including revenue of $0.4 million and a net loss of $59 million. The company announced plans for a $250 million at-the-market equity offering and potential debt-for-equity exchanges to fund operations and capacity expansion ahead of commercial flights expected in 2027.
Term
Q3 2026
“Spaceship Apeiron’s arrival at Spaceport America shifts our focus towards operational readiness, as we now prepare for flight test and the launch of commercial spaceflight. With our second spaceship on track to join Apeiron and Eve in late Q2/early Q3 2027, we have initiated near-term growth projects expected to increase capacity from this initial fleet to a rate of 150 spaceflights per year by the end of 2028.”
Michael Colglazier, Chief Executive Officer of Virgin Galactic
Lulu's Fashion Lounge Holdings, Inc. reported a significant decline in net revenue for the thirteen weeks ended September 27, 2026, falling to $58.6 million from $73.6 million in the prior year period. The company's stockholders' equity turned to a deficit of $5.0 million as of September 27, 2026, driven by an accumulated deficit of $272.0 million.
Quantum Cyber N.V. reported a significant increase in revenue to $0.97 million for the nine months ended September 30, 2026, compared to zero in the prior year, though net loss widened to $21.5 million. The company strengthened its balance sheet through $22.2 million in financing activities, primarily from warrant exercises and preferred share issuances, resulting in a total cash position of $4.89 million.
Sunshine Biopharma Inc. reported a net loss of $4.03 million for the nine months ended September 30, 2026, compared to a loss of $3.83 million in the prior year period. While revenues decreased slightly to $26.79 million, the company significantly strengthened its cash position to $14.62 million through public offerings and warrant exercises.
Aethlon Medical reported a net loss of $4.17 million for the six months ended September 30, 2026, compared to $3.25 million in the prior year period, driven largely by increased professional fees. The company is currently pursuing a merger with North Immunology, Inc. and has raised capital through common stock issuances to maintain a cash balance of approximately $6.49 million.
Willamette Valley Vineyards reported a net loss of $3.0 million for the nine months ended September 30, 2026, compared to a $1.7 million loss in the prior year period. Despite a 4.2% increase in net sales to $27.2 million, rising operating expenses and higher cost of sales contributed to a loss applicable to common shareholders of $0.97 per share.
BioStem Technologies reported a significant decline in revenue to $21.7 million for the nine months ended September 30, 2026, compared to $37.4 million in the prior year, resulting in a net loss from operations of $27.1 million. The company is facing liquidity challenges, including an unpaid $10 million clearance payment due to BioTissue and a substantial decrease in cash from $29.5 million to $971,145 over the nine-month period.
For the nine months ended September 30, 2026, Eledon Pharmaceuticals reported a net loss of $74.6 million, a significant increase from the $35.2 million loss in the prior year period, primarily driven by a $11.6 million unfavorable change in the fair value of warrant liabilities. Total assets decreased to $106.6 million from $169.0 million at year-end 2025, reflecting a reduction in cash and short-term investments used to fund ongoing research and development operations.